

Characterization of Clindamycin using TurboDDS on the Agilent 500 Ion Trap LC/MS

Application Note

Pharmaceuticals

Authors

Joseph Stork
Agilent Technologies, Inc.
5301 Stevens Creek Boulevard
Santa Clara, CA 95051
USA

Abstract

The structures of antibiotics such as clindamycin can be explored and confirmed with the use of the 500 Ion Trap LC/MS.

Introduction

Clindamycin is a lincosamide antibiotic that is used against gram-positive and gram-negative anaerobic pathogens and gram-positive aerobes. Its mode of operation is inhibition of bacterial protein synthesis and it is mainly used for antimicrobial purposes. Since the synthesis of clindamycin from lincomycin can result in impurities such as clindamycin B, 7-epiclindamycin and lincomycin, it is useful to be able to characterize the pure drug in the bulk drug form to certify that it has a high level of purity.



Agilent Technologies

Instrumentation

The following instruments were used in this study:

- Agilent 500 Ion Trap LC/MS
- Agilent 212-LC Binary Solvent Delivery Modules (2)
- Built-in 6-port valve and syringe infusion pump

Materials and Reagents

Methanol (p/n A456-4) and water (p/n W6-4) (Optima LC/MS grade) were purchased from Fisher Scientific (Pittsburgh, PA). Clindamycin was provided by Agilent Technologies.

Sample Preparation

A clindamycin standard was prepared at 10 ppm by dissolving 1 mg in 100 mL of 50:50 methanol:water.

LC conditions

LC program: Isocratic
Flow rate: 200 μ L/min
Injection volume: 20 μ L

MS parameters

Ionization mode: ESI positive
Nebulizing gas: 20 psi
Drying gas: 50 psi at 250 °C
Needle: 6000 V
Shield: 600 V
Capillary: 56.4 V
RF loading: 65
Scan parameters: Full scan: m/z 100 to 450
 μ scans averaged: 3 μ scans; 2.20 s/scan

TurboDDS parameters

Survey scan range: m/z 100–450
Capillary: 56.4 V
RF loading: 65%
MSⁿ depth: n=5
Auto mass range: 0n
High resolution: 0n
High resolution mscans: 3 μ scans
Isolation window: 3 m/z

	Breadth	mscans	Start mass	End mass	Threshold
MS ²	1	3	50	2000	20000
MS ³	1	3	50	2000	860
MS ⁴	1	3	50	2000	860
MS ⁵	1	3	50	2000	860

TurboDDS trigger conditions

Threshold: 200,000 counts
Minimum intensity ratio: 1%
Isotopic equivalence: 3 m/z

Results and Discussion

Full scan MS spectra, MS/MS spectra of the protonated molecule and MS³ spectra of prominent product ions were first generated by infusing the standard at 20 μ L/minute for two minutes using the built-in syringe pump. The TurboDDS run was made by flow injection of 20 μ L on the built-in six-port valve through a flow of 200 μ L/min to produce peaks for compound recognition.

The standard was infused in MS mode to yield the molecular weight and some structural information to trace the fragmentation of clindamycin.




Figure 1. Clindamycin MW 424 u.





Figure 2. Protonated molecule m/z 425.2 is $[M+H]^+$.



m/z 126

Figure 3. Clindamycin fragment m/z 126.

An easily generated fragment at m/z 126.1 was observed in source at optimum capillary voltage for the protonated molecule. There are many possible pathways to this fragment.

To explore the structure further, MS/MS spectra were collected for clindamycin (precursor m/z 425) to investigate the most abundant fragments (Figure 4).




Figure 4. MS/MS spectrum of clindamycin.

The most likely chemical compositions of the product ions include:

- m/z 407 $[M+H-H_2O]^+$
- m/z 389 $[M+H-HCl]^+$
- m/z 377 $[M+H-HSCH_3]^+$
- m/z 341 $[M+H-HSCH_3-HCl]^+$
- m/z 335 $[M+H-CHOHCHSCH_3]^+$
- m/z 299 $[M+H-HCl-CHOHCHSCH_3]^+$

MS³ spectra were collected for each major MS/MS product ion, and the structural cleavage was correlated with those fragments to further explore the fragmentation pathways. Figures 5 through 15 show the MS³ spectra collected for clindamycin.




Figure 5. MS³ spectrum of m/z 407.




Figure 6 MS³ spectrum of m/z 389.2.




Figure 7. Structure for clindamycin fragment with m/z 389.




Figure 10. MS³ spectrum of m/z 341.3.




Figure 11. Structure for clindamycin fragment with m/z 341.




Figure 8. MS³ spectrum of m/z 377.2.




Figure 9. Structure for clindamycin fragment with m/z 377.




Figure 12. MS³ spectrum of m/z 335.2.




Figure 13. Structure for clindamycin fragment with m/z 335.




Figure 14. MS³ of m/z 299.




Figure 15. Structure for clindamycin fragment with m/z 299.

High Resolution and Data Dependent Scanning

TurboDDS is a data dependent scanning program with useful features for assisting in structural elucidation:

- High-resolution display of the molecular ion isotope pattern.
- Automatic triggering of the MSⁿ spectra acquisition when a chromatographic peak of sufficient signal is encountered.
- Organization of the series of spectra acquired in convenient cascading displays.
- Ion Tree report to highlight major product ions and neutral losses.

A high-resolution display of the molecular ion allows confirmation of naturally occurring isotopes in the formula. The




Figure 16. MS/MS spectrum of m/z 425. The carrot shown at m/z 377.2 peak indicates that further MSⁿ scans were performed for that ion.




Figure 17. High-resolution spectrum for m/z 425.2.

chlorine and the sulfur in the formula of clindamycin constitute a combined 32.4 and 4.4 percent relative abundance of the [M + 2]⁺ ion. Oxygen also contributes 0.2 percent per atom.

The product ion tree report combines all of the data acquired in a TurboDDS analysis. It allows the organization of all of ions elucidated and gives ion and neutral loss patterns to help confirm the structure.




Figure 18. Product ion tree report for m/z 425.

Conclusion

The structures of antibiotics such as clindamycin can be explored and confirmed with the use of the Agilent 500 Ion Trap LC/MS. With the addition of TurboDDS software, all the necessary components can be acquired on an unknown sample where the chromatographic peak triggers further analysis and provides clear report organization of MS^n and high-resolution data.

Reference

- 1 "Separation and characterization of clindamycin and related impurities in bulk drug by high-performance liquid chromatography-electrospray tandem mass spectrometry." *Journal of Pharmaceutical and Biomedical Analysis* 41, 2006, 1116–1123.

For More Information

These data represent typical results. For more information on our products and services, visit our Web site at www.agilent.com/chem.

www.agilent.com/chem

Agilent shall not be liable for errors contained herein or for incidental or consequential damages in connection with the furnishing, performance, or use of this material.

Information, descriptions, and specifications in this publication are subject to change without notice.

© Agilent Technologies, Inc., 2011
 Printed in the USA
 February 24, 2011
 SI-1582